Aspirin therapy in primary cardiovascular disease prevention A position paper of the ESC Working Group Thrombosis
|
|
- Allyson Bishop
- 5 years ago
- Views:
Transcription
1 Halvorsen S. et al., Online Supplemental Material, page 1 Aspirin therapy in primary cardiovascular disease prevention A position paper of the ESC Working Group Thrombosis Short title: aspirin in primary prevention Sigrun Halvorsen Department of Cardiology, Oslo University Hospital Ulleval, Oslo, Norway - sigrun.h@online.no Felicita Andreotti - Department of Cardiovascular Science, Catholic University, Rome, Italy felicita.andreotti@iol.it Jurriën M. ten Berg - Department of Cardiology, St Antonius Hospital, Nieuwegein, the Netherlands - jurtenberg@gmail.com Marco Cattaneo - Medicina 3, Ospedale San Paolo. Dipartimento di Scienze della Salute, Università degli Studi di Milano. Milan, Italy - marco.cattaneo@unimi.it Sergio Coccheri - Department of Cardiovascular Disease, University of Bologna, Italy coccheris.angio@libero.it Roberto Marchioli Quintiles Pescara, Italy - marchioli.roberto@gmail.com Joao Morais - Santo Andre s Hospital, Leiria, Portugal - jaraujomorais@gmail.com Freek W.A. Verheugt, Department of Cardiology, Heartcenter, Onze Lieve Vrouwe Gasthuis (OLVG), Amsterdam, Netherlands - f.w.a.verheugt@olvg.nl Raffaele de Caterina - Institute of Cardiology, G. D Annunzio University Chieti, Italy rdecater@unich.it Correspondence: Raffaele De Caterina, MD, PhD Institute of Cardiology C/o Ospedale SS. Annunziata Via dei Vestini Chieti, Italy Tel FAX: rdecater@unich.it ONLINE SUPPLEMENTAL MATERIAL 1
2 Halvorsen S. et al., Online Supplemental Material, page 2 Oral anticoagulants in primary prevention Only one proper randomized trial, the Thrombosis Prevention Trial (TPT) (1), has been carried out in primary prevention of associated with atherothrombosis with oral anticoagulants (vitamin K antagonists). In British general practice, 5,085 healthy males aged 45 to 69 and at the highest quintile of CV risk were randomised to double-blind warfarin (target INR 1.5), low-dose aspirin (75 mg daily), both or neither, and followed for nearly 7 years. Warfarin without aspirin reduced all ischemic heart disease from 13.3 to 10.3 per 1000 person-years compared to those receiving placebo (22% reduction, 95% confidence interval (CI) -4 to 41). This reduction was of the same magnitude as that obtained with aspirin. Major bleeding was seen in 9 men on warfarin and 4 on placebo. Because of this increase in bleeding, vitamin K antagonists are generally not recommended in primary prevention, and will not be discussed further in this review. The efficacy of aspirin for primary prevention of The Physicians Health Study (PHS) randomly allocated, in a double-blind fashion, 22,071 male physicians 40 years of age or older, to receive 325 mg of aspirin every other day or placebo (2). The average follow-up amounted to 60 months. The risk of MI was reduced by 44% in the aspirin group compared to placebo (relativ risk, 0.56; 95% CI, 0.45 to 0.70; P< ). The risk of stroke was slightly increased numerically, but not significantly (P = 0.15). In the non-blinded British Doctors Trial (BDT), 5,139 male physicians under the age of 80 received aspirin 500 or 300 mg daily or no treatment during 6 years (3). Treatment with aspirin did not influence the incidence of MI: 5.0% for aspirin and 5.2% for no aspirin (relative risk reduction 4%, 95% CI 24 to 27%, P = N.S.). Total mortality, however, was 14% lower in the aspirin group (P = N.S.). In the Thrombosis Prevention Trial (TPT) aspirin reduced the incidence of new ischaemic heart disease from 13.3 to 10.2 per 1000 person-years compared to placebo (23% reduction, 95% CI -3 to 42%) (1). In the Hypertension Optimal Treatment (HOT) trial, 18,790 male and female individuals aged 50 to 80 years old and with well-managed hypertension were randomised to 75 mg aspirin daily or placebo (4). After nearly 4 years, MI was reduced by 36% (95% CI 15 to 51%) from 1.4 to 0.9% (4). 2
3 Halvorsen S. et al., Online Supplemental Material, page 3 The Primary Prevention Project (PPP) (5) was carried out in general practice in Italy to establish the role of aspirin in primary prevention, but was prematurely halted because of the publication of other positive studies (1,4). In 4,495 healthy males and females over the age of 65, aspirin 100 mg daily or placebo was given for 3 years. Aspirin reduced the rate of MI by 25% (95% CI -26 to 55%) (5). The Womens Health Study (WHS) randomly allocated, in a double-blind fashion, 39,876 women 45 years of age or older to 100 mg of aspirin every other day or placebo (6). The average follow-up amounted to 10 years. A reduction of the risk of MI was not found: 1.0 vs 1.0% (relative risk 1.02, 95% CI 0.84 to 1.25, P = 0.83). The risk of stroke was reduced by 17% (relative risk 0.83, 95% CI 0.69 to 0.99, P = 0.04) (6). In the Prevention of Progression of Arterial Disease and Diabetes (POPADAD) trial (7), 1276 individuals with type 1 or type 2 diabetes and an ankle brachial pressure index of 0.99 or less but no symptomatic CV disease were randomised to aspirin or placebo for a median follow-up time of 6.7 years. The authors used two hierarchial composite primary end points: death from coronary heart disease or stroke, non-fatal MI or stroke, or above-ankle amputation for critical limb ischaemia; and death from coronary heart disease or stroke. There was no significant difference between groups in the occurrence of either of the primary end points: 18.2% on aspirin vs 18.3% on placebo (P=0.86), and 6.7% on aspirin vs 5.5% on placebo (P=0.36), respectively (7). The Japanese Primary Prevention of Atherosclerosis with Aspirin for Diabetes (JPAD) (8) trial randomised 2539 patients with type 2 diabetes, without a history of atherosclerotic disease, to aspirin 81- or placebo. After a median follow-up of 4.4 years, 5.4% of patients in the aspirin group vs 6.7% in the non-aspirin group experienced an atherothrombotic event (HR 0.80, 95% CI , P=0.16). The combined end point of fatal coronary events and fatal cerebrovascular events was significantly reduced in the aspirin group (HR 0.10; 95% CI, ; P=0.0037). Finally, in the Aspirin for Asymptomatic Atherosclerosis Trialists study (AAA) (9), 3350 individuals with a low ankle brachial pressure index ( 0.95) but without clinical CV disease, were randomly assigned to 100 mg aspirin once daily or placebo. The primary end point was a composite of initial fatal or non-fatal coronary event or stroke or revascularisation. Two secondary end points were (1) all initial vascular events defined as a composite of a primary end point event or angina, intermittent 3
4 Halvorsen S. et al., Online Supplemental Material, page 4 claudication, or transient ischemic attack; and (2) all-cause mortality. After a mean follow-up time of 8.2 years, no statistically significant difference in the occurrence of the primary end point events (13.7 events per 1000 person-years in the aspirin group vs 13.3 in the placebo group; HR 1.03; 95% CI ) or all-cause mortality was found between the groups. An additional, now remote trial, the Early Treatment Diabetic Retinopathy Study (ETDRS) report 14 (10), is sometimes considered for aspirin in the setting of primary prevention. In this multicenter, randomised clinical trial of aspirin vs placebo, 3711 men and women between the ages of 18 and 70 years with a clinical diagnosis of diabetes mellitus were eligible (30% considered to have type 1 diabetes, 31% having type 2, and 39% a type which could not be determined definitely). Forty-nine % of subjects recruited in the aspirin arm and 48.5% in the placebo arm reported a history of, but this included the presence of hypertension or the use of diuretics and other anti-hypertensive agents, and no separate analysis for truly primary and secondary prevention (as defined above) was available. Patients were here randomly assigned to aspirin (two 325-mg tablets once per day) or placebo. The main outcome measure was mortality from all causes. Other outcome variables included cause-specific mortality and CV events. Here the estimate of relative risk for total mortality for aspirin patients compared with placebo- patients for the entire study period (an average followup of 5 years, range 4 to 9) was 0.91 (99% confidence interval, 0.75 to 1.11). Larger differences, but still not statistically significant, were noted for the occurrence of fatal and non-fatal MI, for which the estimate of relative risk was 0.83 for the entire follow-up period (99% confidence interval, 0.66 to 1.04). The authors concluded that the effects of aspirin on any of the cardiovascular events were not substantially different from the effects observed in other previous studies that included mainly nondiabetic persons, without evidence of harmful effects of aspirin, thus supporting, according to the authors, the use of aspirin for persons with diabetes at increased risk of (10). This study was not included in the present analysis (similarly as in other meta-analyses, listed below), because no separate data for primary and secondary prevention were here available. 4
5 Halvorsen S. et al., Online Supplemental Material, page 5 Extended Legend to Figure 1: Relationships between magnitude of antithrombotic benefit and of bleeding risk connected with the use of aspirin (on the ordinate) and absolute cardiovascular risk (on the abscissa), in various subsets of subjects in primary prevention. The magnitude of antithrombotic benefit and of bleeding risk connected with the use of aspirin are plotted on the ordinate as a function of the absolute cardiovascular risk (on the abscissa), in various subsets of subjects in primary prevention. The commonly adopted approach of computer-aided literature search was applied to retrieve all published RCTs. Nine trials have been included in the present analysis, with the following criteria for inclusion: (1) designed aspirin treatment in the primary prevention of cardiovascular disease, (2) exclusion of patients with prior myocardail infarction or cerebrovascular stroke, (2) randomized design, (3) recorded incidence of cardiovacular events, (4) at least 1,000 patients included in the trial and (5) at least 12 months of follow-up Trials included: Trials included: U.S. Physicians Health Study-PHS (2), British Doctors Trial-BDT (3), Thrombosis Prevention Trial-TPT (1), HOT study (4), Primary Prevention Project-PPP (5), Women s Health Study (6), POPAPAD Study (7), JPAD Study (8), and Aspirin for Asymptomatic Atherosclerosis (AAA) trial (9). Data from the Swedish Angina Pectoris Aspirin Trial (SAPAT) of aspirin in stable angina (11), are also included as reference to the lowest published cardiovascular (CV) risk category in secondary CV prevention. To examine the strength of the association between treatment effects of aspirin on CV events, major gastrointestinal bleeding, and total major bleeding with the level of CV risk per 100 person-years in the control arm of the trials, we fitted univariate inverse variance-weighted linear regressions of the risk difference for the outcome events per 100 person-years between the two experimental arms of each study as a dependent variable against the aforementioned explanatory variable. Results have been reported together with their 95% confidence intervals (CIs). Adjustment for daily aspirin dose tested in the trials did not materially change the results. Size of circles is proportional to the inverse of variance of the risk difference. All analyses were carried out with a specifically designed software written in SAS language. Notice that the risk of major gastro-intestinal bleeding events requiring transfusion (purple line) in the various studies, although increasing as a function of cardiovascular risk as pointed out in the ATT Collaboration meta-analysis (12), is less dependent on the baseline CV risk than the absolute CV benefit (red line) see the different slopes of the two regression lines. These estimates can be used to 5
6 Halvorsen S. et al., Online Supplemental Material, page 6 identify a threshold value of absolute CV risk below which the use of aspirin in primary CV prevention is unattractive, since associated with a quite uncertain benefit-risk ratio. Equally, an absolute CV risk above 2 major cardiovascular events / 100 is an area where the separation of the regression lines depicting the benefit (red line) and the risk (purple and green lines) separate considerably, defining an area of theoretical net clinical benefit despite the prescription uncertainty deriving from the lack of trials. Red arrow denotes the area where benefit likely equals risk, yellow area denotes area of prescription uncertainty, and green arrow denotes the area where benefit most likely exceeds risk. Abbreviations and notes: Absolute Risk Change is absolute risk reduction for CV events and absolute risk increase for major gastrointestinal bleeds and total major bleeds. Continuous Line = Linear Regression; Dotted line = Lower and Higher 95% CI. CV = Cardiovascular; GI = Gastrointestinal; CI = Confidence Interval; ASA = Acetylsalicylic Acid (aspirin). 6
7 Halvorsen S. et al., Online Supplemental Material, page 7 e 1: Primary relevant data of currently available primary prevention trials with aspirin in cardiovascular disease ^ Reference Mean duration of follow-up (years) ASPIRIN / year Major cardiovascular events * CONTROLᶲ / year Absolute risk reduction (placebo - aspirin) NNT (with decimals) NNT (integer number) 3 5, ,0843 1,5324 0, ,0860 1,5630 0, , , ,0278 0,5563 0, ,0335 0,6707 0, , , , ,0413 1,0863 0, ,0453 1,1909 0, , , , ,0896 1,3998 0, ,1024 1,5994 0, , , , ,0202 0,5615 0, ,0282 0,7835 0, , , , ,0239 0,2369 0, ,0262 0,2592 0, , , , ,1646 2,4564 0, ,1693 2,5266 0, , , , ,0539 1,2330 0, ,0673 1,5411 0, , , , ,1081 1,3178 0, ,1051 1,2814 0, , , , ,1100 2,6193 0, ,1550 3,6898 0, , ,41 93 Reference Mean duration of follow-up (years) / year / year Absolute excess of major bleeding due to aspirin (aspirinplacebo) NNH (with decimals) NNH (integer numbers) 3 5, ,0085 0,1538 0, ,0041 0,0744 0, , , ,0043 0,0870 0, ,0025 0,0508 0, , , , ,0138 0,3640 0, ,0080 0,2102 0, , , , ,0079 0,1228 0, ,0051 0,0800 0, , , , ,0108 0,2995 0, ,0026 0,0735 0, , , , ,0089 0,0884 0, ,0066 0,0655 0, , , , ,0470 0,7018 0, ,0533 0,7954 0, , , , ,0135 0,3083 0, ,0055 0,1254 0, , , , ,0203 0,2475 0, ,0119 0,1456 0, , , , ,0198 0,4719 0, ,0127 0,3017 0, , , Reference Mean duration of follow-up (years) ASPIRIN ASPIRIN / year Total major bleeding CONTROLᶲ Major gastrointestinal bleeding CONTROLᶲ / year Absolute excess of major GI bleeding due to aspirin (aspirin-placebo) NNH (with decimals) NNH (integer numbers) 3 5, ,0058 0,1060 0, ,0041 0,0744 0, , , ,0000 0,0000 0, ,0000 0,0000 0, , missing missing 4 3, ,0082 0,2156 0, ,0039 0,1037 0, , , , ,0059 0,0921 0, ,0043 0,0677 0, , , , ,0076 0,2121 0, ,0022 0,0612 0, , , , ,0064 0,0631 0, ,0046 0,0452 0, , , , ,0439 0,6550 0, ,0486 0,7252 0, , , , ,0032 0,0725 0, ,0000 0,0000 0, , , , ,0054 0,0655 0, ,0048 0,0582 0, , , , ,0109 0,2596 0, ,0058 0,1392 0, , , Reference Mean duration of follow-up (years) ASPIRIN / year / year Absolute excess of hemorrhagic stroke due to aspirin (aspirin-placebo) NNH (with decimals) NNH (integer numbers) 3 5, ,0029 0,0001 0, ,0023 0,0001 0, , , ,0021 0,0002 0, ,0011 0,0001 0, , , ,8 NA NA , ,0055 0,0011 0, ,0024 0,0005 0, , , , ,0009 0,0002 0, ,0013 0,0003 0, , , , ,0026 0,0001 0, ,0021 0,0000 0, , , , ,0000 0,0000 0, ,0031 0,0002 0, , , ,37 NA NA , ,0030 0,0001 0, ,0024 0,0001-0, , , ,2 NA NA ainable: GI: gastrointestinal; NNT: number needed to treat; NNH: number needed to harm AT trial in secondary prevention as a reference myocardial infarction, non-fatal stroke exception of the British Doctors Trial where no drug given in the control arm t on any prespecified endpoint" min E nor treatment with beta carotene significantly modified the effect of Aspirin on the endpiont" 50 mounths = 4,2 years 60,2 mounths = 5 years Hemorrhagic stroke CONTROLᶲ 7
8 Halvorsen S. et al., Online Supplemental Material, page 8 Online Supplemental Table 2: Ongoing randomized controlled trials of aspirin in the primary prevention of CV events. Individuals without ARRIVE Aspirin to Reduce Risk of Initial Vascular Event ASPREE Aspirin in Reducing in the Elderly JPPP Japanese Primary Prevention Project ASCEND A Study of Cardiovascu lar in Diabetes ACCEPT-D Aspirin and simvastatin Combinatio n for CV Event Prevention Trial in Diabetes ENVIS-ion Elderly NeuroVascu lar Imaging Study (ASPREE Substudy) DESIGN 1:1 Double blind control 1:1 Double blind control Open label Controlled Blind adjudication Double blind control 2x2 Factorial Open label Controlled 1:1 Double blind control NUMBER of SUBJECTS ~ 12,000 No known Without diabetes ~ 15,000 No overt AGE RISK FACTORS Men > 55 y with 2-4 RFs Women > 60 y with > 3 RFs Men and women > 70 y Multiple RFs 14,466 Men and women y with HT, diabetes or dyslipidemia 15,480 Type I and II diabetes No overt 5,170 Type I and II diabetes on, or eligible for, statin therapy No overt ~ 600 No overt Normal cognitive function Men and women > 40 y With diabetes Men and women > 50 y With diabetes on statin therapy Men and women > 70 y Multiple RFs ASA DOSE CONTROL No ASA No ASA OTHER THERAPIES Omega-3 fatty acids 1 g daily or olive oil placebo Simvastatin 20 mg daily in all for LDL-C > 100 mg/dl PRIMARY EFFICACY END POINT Nonfatal MI Nonfatal stroke CV death Major adverse CV events and dementia Nonfatal MI Nonfatal stroke CV death Nonfatal MI Nonfatal stroke* CV death Nonfatal MI Nonfatal stroke CV death Hospital admission for CV cause Brain lesions at magnetic resonance imaging FOLLOW-UP START / END ~ 5 years Event driven ~ 5 years ~ 4 years Enrollment ~ 7.5 years Start 2005 End ~ 2017 Event driven ~ 3 years Start 2008 * excluding confirmed cerebral hemorrhage ASA=aspirin or acetylsalicylic acid; CV=cardiovascular; =cardiovascular disease; diabetes=diabetes mellitus; EP=endpoint; HT=hypertension; LDL-C=low density lipoprotein cholesterol; MI=myocardial infarction; N=number; po=per os; preop.=preoperatively; postop.=postoperatively; RFs= cardiovascular risk factors; y=years. 8
9 Halvorsen S. et al., Online Supplemental Material, page 9 REFERENCES 1. The Medical Research Council's General Practice Research Framework. Thrombosis Prevention Trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998;351: Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group. N Engl J Med 1989;321: Peto R, Gray R, Collins R et al. trial of prophylactic daily aspirin in British male doctors. Br Med J (Clin Res Ed) 1988;296: Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998;351: Primary Prevention Project Investigators. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001;357: Ridker PM, Cook NR, Lee IM et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005;352: Belch J, MacCuish A, Campbell I et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008;337:a Ogawa H, Nakayama M, Morimoto T et al. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA 2008;300: Fowkes FG, Price JF, Stewart MC et al. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;303: ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report 14. JAMA 1992;268: Juul-Moller S, Edvardsson N, Jahnmatz B et al. Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. Lancet 1992;340: Baigent C, Blackwell L, Collins R et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:
SESSION 3 11 AM 12:30 PM
SESSION 3 11 AM 12:30 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationAspirin to Prevent Heart Attack and Stroke: What s the Right Dose?
The American Journal of Medicine (2006) 119, 198-202 REVIEW Aspirin to Prevent Heart Attack and Stroke: What s the Right Dose? James E. Dalen, MD, MPH Professor Emeritus, University of Arizona, Tucson
More informationNew York Cardiovascular Symposium New York, December New York Hilton Midtown
New York Cardiovascular Symposium New York, December 11-13 2015 New York Hilton Midtown Session IV: Trends and Challenges of Prevention December 11 2015 15:15-17:30 Aspirin Therapy in Primary Cardiovascular
More informationSESSION 5 2:20 3:35 PM
SESSION 5 2:20 3:35 PM for the Primary Prevention of Cardiovascular Disease: A Personalized Approach SPEAKER Samia Mora MD, MHS Presenter Disclosure Information The following relationships exist related
More informationUpdate in Cardiology Pharmacologic Management of Cardiovascular Risk. Christopher C. Roe, MSN, ACNP
Update in Cardiology Pharmacologic Management of Cardiovascular Risk Christopher C. Roe, MSN, ACNP Objectives 1. Verbalize understanding of new pharmacologic guidelines in the treatment of hypertension
More informationSummary. Log in. PlumX Metrics. Background
Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of ca... 1/12 Log in ARTICLES Use of aspirin to reduce risk of initial vascular events in patients at moderate risk
More information9/29/2015. Primary Prevention of Heart Disease: Objectives. Objectives. What works? What doesn t?
Primary Prevention of Heart Disease: What works? What doesn t? Samia Mora, MD, MHS Associate Professor, Harvard Medical School Associate Physician, Brigham and Women s Hospital October 2, 2015 Financial
More informationAntiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease. Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.
Antiplatelet Therapy in Primary CVD Prevention and Stable Coronary Artery Disease Καρακώστας Γεώργιος Διευθυντής Καρδιολογικής Κλινικής, Γ.Ν.Κιλκίς Primary CVD Prevention A co-ordinated set of actions,
More informationArteriopatie periferiche. Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante
Arteriopatie periferiche Trattamento delle arteriopatie periferiche: AVK versus Antiaggregante Anna Falanga USC Immunoematologia e Medicina Trasfusionale ASST Papa Giovanni XXIII, Bergamo Obiettivi della
More informationDiabete ed ASA: cosa c è di nuovo?
Università Magna Græcia di Catanzaro Dipartimento di Medicina Sperimentale e Clinica Cattedra di Medicina Interna ed U.O. Malattie Cardiovascolari Scuola di Specializzazione in Geriatria Prof. Francesco
More informationUpdate sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico
Update sulla terapia antiipertensiva e antiaggregante nel paziente cardiometabolico G. Mazzanti UO Cardiologia Ospedale SS. Annunziata, Cento (FE) AUSL di Ferrara Antiplatelet therapy Aspirin Aspirin:
More informationORIGINAL INVESTIGATION. An Update on Aspirin in the Primary Prevention of Cardiovascular Disease
ORIGINAL INVESTIGATION An Update on in the Primary Prevention of Cardiovascular Disease Rachel S. Eidelman, MD; Patricia R. Hebert, PhD; Steven M. Weisman, PhD; Charles H. Hennekens, MD, DrPH Background:
More informationAntiplatelet agents treatment
Session III Comprehensive management of diabetic patients Antiplatelet agents treatment Chonnam National University Hospital Department of Internal Medicine Dong-Hyeok Cho CONTENTS Introduction Prothrombotic
More informationShould we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway
Should we prescribe aspirin and statins to all subjects over 65? (Or even all over 55?) Terje R.Pedersen Oslo University Hospital Oslo, Norway The Polypill A strategy to reduce cardiovascular disease by
More informationDr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre
Dr Julia Hopyan Stroke Neurologist Sunnybrook Health Sciences Centre Objectives To learn what s new in stroke care 2010-11 1) Acute stroke management Carotid artery stenting versus surgery for symptomatic
More informationAspirine pour tous les patients à haut risque?
Aspirine pour tous les patients à haut risque? Gilles Lemesle, Centre Hémodynamique, CHRU de Lille Cliquez pour modifier le style des sous titres du masque The clinical point of view Ratio Ischaemic events
More informationMacrovascular Residual Risk. What risk remains after LDL-C management and intensive therapy?
Macrovascular Residual Risk What risk remains after LDL-C management and intensive therapy? Defining Residual Vascular Risk The risk of macrovascular events and microvascular complications which persists
More informationThe Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease
Interventional Cardiology and Cath Labs The Changing Landscape of Managing Patients with PAD- Update on the Evidence and Practice of Care in Patients with Peripheral Artery Disease Manesh R. Patel MD Chief,
More information7 th Munich Vascular Conference
7 th Munich Vascular Conference Secondary prevention of major cardiovascular events in patients with CHD or PAD - What can we learn from EUCLID and COMPASS, evaluating Clopidogrel, Ticagrelor and Univ.-Prof.
More informationThe JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009
The JUPITER trial: What does it tell us? Alice Y.Y. Cheng, MD, FRCPC January 24, 2009 Learning Objectives 1. Understand the role of statin therapy in the primary and secondary prevention of stroke 2. Explain
More informationRole of Clopidogrel in Acute Coronary Syndromes. Hossam Kandil,, MD. Professor of Cardiology Cairo University
Role of Clopidogrel in Acute Coronary Syndromes Hossam Kandil,, MD Professor of Cardiology Cairo University ACS Treatment Strategies Reperfusion/Revascularization Therapy Thrombolysis PCI (with/ without
More informationPrevenzione secondaria dell ischemia cerebrale di origine arteriosa. Marco Cattaneo. Ospedale San Paolo Università degli Studi di Milano
Prevenzione secondaria dell ischemia cerebrale di origine arteriosa Marco Cattaneo Ospedale San Paolo Università degli Studi di Milano Cerebral Ischemia of Arterial Origin (CIAO) Cumulative meta-analysis
More informationTo provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
ACETYL SALICYLIC ACID TARGET AUDIENCE: All Canadian health care professionals. OBJECTIVE: To provide information on the use of acetyl salicylic acid in the treatment and prevention of vascular events.
More informationAspirin: Its risks, benefits, and optimal use in preventing cardiovascular events
REVIEW CME CREDIT EDUCATIONAL OBJECTIVE: Readers will prescribe aspirin for secondary and primary prevention according to evidence-based guidelines KI PARK, MD Division of Cardiovascular Medicine, University
More informationA new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
More informationASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study
More informationJ. Michael Gaziano, M.D., M.P.H. European Society of Cardiology August 26 th 2018
ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events): A Study to Assess the Efficacy and Safety of Aspirin in Patients at Moderate Risk of Cardiovascular Disease J. Michael Gaziano, M.D., M.P.H.
More informationCost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia
Cost-effectiveness of evolocumab (Repatha ) for hypercholesterolemia The NCPE has issued a recommendation regarding the cost-effectiveness of evolocumab (Repatha ). Following NCPE assessment of the applicant
More informationcor et vasa 55 (2013) e190 e195 Available online at journal homepage:
Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/crvasa Review Article Special issue: Thrombosis Current opinion on aspirin in primary prevention of atherosclerotic cardiovascular
More informationRESEARCH. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials Giorgia De Berardis, research officer, 1 Michele Sacco, research officer,
More informationIs there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
More information03/30/2016 DISCLOSURES TO OPERATE OR NOT THAT IS THE QUESTION CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE
CAROTID INTERVENTION IS INDICATED FOR ASYMPTOMATIC CAROTID OCCLUSIVE DISEASE Elizabeth L. Detschelt, M.D. Allegheny Health Network Vascular and Endovascular Symposium April 2, 2016 DISCLOSURES I have no
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationTriple Therapy After PCI in AF: A Quagmire Soon to be Drained
Triple Therapy After PCI in AF: A Quagmire Soon to be Drained Freek W.A. Verheugt Department of Cardiology, Onze Lieve Vrouwe Gasthuis (OLVG) Amsterdam, Netherlands DISCLOSURES FOR FREEK W. A. VERHEUGT
More informationA Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan
ORIGINAL ARTICLE A Health Economic Evaluation of Aspirin in the Primary Prevention of Cardiovascular Disease in Japan Kiichiro Tsutani 1, Ataru Igarashi 1, Keita Fujikawa 2, Thomas Evers 3, Maria Kubin
More informationExperiences with interim trial monitoring, particularly with early stopped trials
Experiences with interim trial monitoring, particularly with early stopped trials 1 Robert J Glynn, ScD Divisions of Preventive Medicine and Pharmacoepidemiology & Pharmacoeconomics, Brigham & Women s
More informationThe role of statins in patients with arterial hypertension
Invited review The role of statins in patients with arterial hypertension Trygve B. Tjugen 1, Sigrun Halvorsen 1, Reidar Bjørnerheim 1, Sverre E. Kjeldsen 1, 2 1University of Oslo, Department of Cardiology,
More informationJohn J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam
Latest Insights from the JUPITER Study John J.P. Kastelein MD PhD Professor of Medicine Dept. of Vascular Medicine Academic Medial Center / University of Amsterdam Inflammation, hscrp, and Vascular Prevention
More informationRegulatory Hurdles for Drug Approvals
Regulatory Hurdles for Drug Approvals William R. Hiatt, MD Professor of Medicine/Cardiology University of Colorado School of Medicine President, CPC Clinical Research 25 min Conflicts CPC Clinical Research
More informationDownloaded from:
Antithrombotic Trialists Collaboration. (inc. Meade, TW), (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high
More informationAspirin for cardiovascular disease prevention
POSITION STATEMENT Aspirin for cardiovascular disease prevention Joseph Hung, for the Medical Issues Committee of the National Heart Foundation of Australia RANDOMISED CONTROLLED TRIALS have proven that
More informationCardiovascular Risk Reduction in Women
Cardiovascular Risk Reduction in Women Karol E. Watson, MD, PhD Assistant Professor of Medicine/ Division of Cardiology Co-director, UCLA Program in Preventive Cardiology Director, Women s Cardiovascular
More informationAll medications are a double-edged sword with risks
Menopause: The Journal of The North American Menopause Society Vol. 14, No. 5, pp. 1/14 DOI: 10.1097/gme.0b013e31802e8508 * 2007 by The North American Menopause Society REVIEW ARTICLE Postmenopausal hormone
More informationStatins in the elderly : Is there a rationale?
Statins in the elderly : Is there a rationale? Pr B Boland After a communication by Dr. Manfred Gogol EAMA, Sion, June, 2006 1 RCTs with Statins Meta-Analysis, 1999 182 abstracts or research papers 29
More informationNON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK. Advances in Cardiac Arrhythmias and Great Innovations in Cardiology
NON STEROIDEAL ANTI-INFLAMMATORY DRUGS AND CARDIOVASCULAR RISK Advances in Cardiac Arrhythmias and Great Innovations in Cardiology Torino, October 15, 2016 Giuseppe Di Pasquale Direttore Dipartimento Medico
More informationCHOLESTEROL-LOWERING THERAPHY
CHOLESTEROL-LOWERING THERAPHY TRIALS NUMBER OF PARTICIPANTS NUMBER OF WOMEN PERCENTAGE OF WOMEN MEAN AGE MEAN - (YEARS) TRIALS WITH ANALYSIS BY GENDER N, (%) 50,194 15,036 30.0% 60.8 3.2 1/ 6 (16.7%) HR
More informationThe updated guidelines from the National
BEYOND NCEP ATP III: LESSONS LEARNED AND FUTURE DIRECTIONS * Benjamin J. Ansell, MD, FACP ABSTRACT The National Cholesterol Education Program (NCEP) Third Adult Treatment Panel (ATP III) guidelines provide
More informationClopidogrel has been evaluated in clinical trials that included cardiovascular patients
REVIEW ARTICLE Comparative Benefits of Clopidogrel and Aspirin in High-Risk Patient Populations Lessons From the CAPRIE and CURE Studies Jack Hirsh, CM, MD, FRCPC, FRACP, FRSC, DSc; Deepak L. Bhatt, MD,
More informationPlacebo-Controlled Statin Trials EXPLAINING THE DECREASE IN DEATHS FROM CHD! PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN EXPLAINING THE DECREASE IN
PREVENTION OF CARDIOVASCULAR DISEASE IN WOMEN Robert B. Baron MD MS Professor and Associate Dean UCSF School of Medicine Declaration of full disclosure: No conflict of interest EXPLAINING THE DECREASE
More informationConflicts of Interest: None. Aspirin, primary prevention and USPSTF. Primary prevention of ASCVD is important
Aspirin, primary prevention and USPSTF Presented by: Craig Williams, PharmD., BCPS., FNLA; February 2017 Conflicts of Interest: None Primary prevention of ASCVD is important Myocardial Infarction Incidence
More informationASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes
ASCEND A randomized trial of omega-3 fatty acids (fish oil) versus placebo for primary cardiovascular prevention in 15,480 patients with diabetes Jane Armitage and Louise Bowman on behalf of the ASCEND
More informationPreventive Cardiology Scientific evidence
Preventive Cardiology Scientific evidence Professor David A Wood Garfield Weston Professor of Cardiovascular Medicine International Centre for Circulatory Health Imperial College London Primary prevention
More informationP S Sanmuganathan, P Ghahramani, P R Jackson, E J Wallis, L E Ramsay. Keywords: aspirin; coronary heart disease; primary prevention; meta-analysis
Heart 2001;85:265 271 265 Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials P S Sanmuganathan,
More informationMRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in high-risk individuals: a randomised placebocontrolled
Articles MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial Heart Protection Study Collaborative Group* Summary
More informationESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future
ESC Geoffrey Rose Lecture on Population Sciences Cholesterol and risk: past, present and future Rory Collins BHF Professor of Medicine & Epidemiology Clinical Trial Service Unit & Epidemiological Studies
More informationIs Lower Better for LDL or is there a Sweet Spot
Is Lower Better for LDL or is there a Sweet Spot ALAN S BROWN MD, FACC FNLA FAHA FASPC DIRECTOR, DIVISION OF CARDIOLOGY ADVOCATE LUTHERAN GENERAL HOSPITAL, PARK RIDGE, ILLINOIS DIRECTOR OF CARDIOLOGY,
More informationUsing DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials
Using DOACs in CAD Patients in Sinus Ryhthm Results of the ATLAS ACS 2, COMPASS and COMMANDER-HF Trials 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La
More informationThe randomized study of efficiency and safety of antithrombotic therapy in
.. [ ] 18 150 160 mg/d 2 mg/d INR 2.0 3.0( 75 INR 1.6 2.5) 704 369 335 420 59.7% 63.3 9.9 19 2 24 2.7% 6.0% P =0.03 OR 0.44 95% CI 0.198 0.960 56% 62% 1.8% 4.6% P =0.04 OR 0.38 95% CI 0.147 0.977 52% 10.6%
More informationHow Long Patietns Will Be on Dual Antiplatelet Therapy?
How Long Patietns Will Be on Dual Antiplatelet Therapy? Ron Waksman,, MD, FACC Professor of Medicine (Cardiology) Georgetown University Associate Director, Division of Cardiology, Washington Hospital Center
More informationBranko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center THE END! CHANGABLE Blood pressure Diabetes Mellitus Hyperlipidemia Atrial fibrillation Nicotine Drug abuse Life style NOT CHANGABLE
More informationDOAC: future possibili indicazioni
DOAC: future possibili indicazioni (IMA, stroke criptogenico, TVC, TV viscerali) Alberto Tosetto UOS Centro Malattie Emorragiche e Trombotiche Divisione di Ematologia, Ospedale S. Bortolo AULSS 8 Berica,
More informationAntiplatelet therapy for peripheral artery disease
Review Article Antiplatelet therapy for peripheral artery disease Rosetta Melfi, Elisabetta Ricottini Unit of Cardiovascular Sciences, Department of Medicine, Campus Bio-Medico University of Rome, Rome,
More informationOptimal medical therapy in patients with stable CAD
Optimal medical therapy in patients with stable CAD Robert Storey Professor of Cardiology, University of Sheffield and Academic Director and Honorary Consultant Cardiologist, Cardiology and Cardiothoracic
More informationAspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission?
Aspirin at the Intersection of Antiplatelet and Anticoagulant Therapy An Act of Commission? Ty J. Gluckman, MD, FACC, FAHA Medical Director, Center for Cardiovascular Analytics, Research and Data Science
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Cardiovascular Risk Factors
Cardiovascular Risk Factors ROB WALKER (Dunedin, New Zealand) Lipid-lowering therapy in patients with chronic kidney disease Date written: January 2005 Final submission: August 2005 Author: Rob Walker
More informationEffective Treatment Options With Add-on or Combination Therapy. Christie Ballantyne (USA)
Effective Treatment Options With Add-on or Combination Therapy Christie Ballantyne (USA) Effective treatment options with add-on or combination therapy Christie M. Ballantyne, MD Center for Cardiovascular
More informationORIGINAL INVESTIGATION. Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study
ORIGINAL INVESTIGATION Self-Selected Posttrial Aspirin Use and Subsequent Cardiovascular Disease and Mortality in the Physicians Health Study Nancy R. Cook, ScD; Patricia R. Hebert, PhD; JoAnn E. Manson,
More informationCVD risk assessment using risk scores in primary and secondary prevention
CVD risk assessment using risk scores in primary and secondary prevention Raul D. Santos MD, PhD Heart Institute-InCor University of Sao Paulo Brazil Disclosure Honoraria for consulting and speaker activities
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationNHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015)
Title of Project: NHS Dumfries & Galloway Aspirin Discontinuation Audit May 2011 (updated August 2015) 1 Reason for the review In the UK, low dose aspirin (75mg) is licensed for the prevention of thrombotic
More informationThe secondary prevention of ischemic stroke is aided by the use of antiplatelet therapy,
NEUROLOGICAL REVIEW SECTION EDITOR: DAVID E. LEASURE, MD Results of the Management of Atherothrombosis With Clopidogrel in High-Risk atients Trial Implications for the Neurologist Marc Fisher, MD The secondary
More informationCarlo Patrono, MD, FESC. New York, 8 th December Catholic University School of Medicine, Rome, Italy. New York Cardiovascular Symposium
Aspirin in Primary and Secondary Cardiovascular Disease Prevention. Still Four Questions: About Enteric-Coated, Indicated Doses, Use in Diabetes, Use in PVD Carlo Patrono, MD, FESC Catholic University
More informationTicagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease
Original Article versus in Symptomatic Peripheral Artery Disease William R. Hiatt, M.D., F. Gerry R. Fowkes, M.D., Gretchen Heizer, M.S., Jeffrey S. Berger, M.D., Iris Baumgartner, M.D., Peter Held, M.D.,
More informationDisclosures. Theodore A. Bass MD, FSCAI. The following relationships exist related to this presentation. None
SCAI Fellows Course December 10, 2013 Disclosures Theodore A. Bass MD, FSCAI The following relationships exist related to this presentation None Current Controversies on DAPT in PCI Which drug? When to
More informationNew evidences in heart failure: the GISSI-HF trial. Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy
New evidences in heart failure: the GISSI-HF trial Aldo P Maggioni, MD ANMCO Research Center Firenze, Italy % Improving survival in chronic HF and LV systolic dysfunction: 1 year all-cause mortality 20
More informationHow would you manage Ms. Gold
How would you manage Ms. Gold 32 yo Asian woman with dyslipidemia Current medications: Simvastatin 20mg QD Most recent lipid profile: TC = 246, TG = 100, LDL = 176, HDL = 50 What about Mr. Williams? 56
More informationLIST OF ABBREVIATIONS
Diabetes & Endocrinology 2005 Royal College of Physicians of Edinburgh Diabetes and lipids 1 G Marshall, 2 M Fisher 1 Research Fellow, Department of Cardiology, Glasgow Royal Infirmary, Glasgow, Scotland,
More informationLow Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1)
Low Dose Rivaroxaban Versus Aspirin, in Addition to P2Y12 Inhibition, in Acute Coronary Syndromes (GEMINI-ACS-1) Caitlin C. Akerman, PharmD PGY2 Cardiology Resident WakeMed Health & Hospitals Raleigh,
More informationDoes High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes?
Late Breaking Clinical Trial Session at AHA 2017 Does High-Intensity Pitavastatin Therapy Further Improve Clinical Outcomes? The REAL-CAD Study in 13,054 Patients With Stable Coronary Artery Disease Takeshi
More informationAPPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES
APPENDIX B: LIST OF THE SELECTED SECONDARY STUDIES Main systematic reviews secondary studies on the general effectiveness of statins in secondary cardiovascular prevention (search date: 2003-2006) NICE.
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 October 2010
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 6 October 2010 CRESTOR 5 mg, film-coated tablet B/30 (CIP code: 369 853-8) B/90 (CIP code: 391 690-0) CRESTOR 10 mg,
More informationJNC 8 -Controversies. Sagren Naidoo Nephrologist CMJAH
JNC 8 -Controversies Sagren Naidoo Nephrologist CMJAH Joint National Committee (JNC) Panel appointed by the National Heart, Lung, and Blood Institute (NHLBI) First guidelines (JNC-1) published in 1977
More informationSTATINS FOR PAD Long - term prognosis
STATINS FOR PAD Long - term prognosis Prof. Pavel Poredos, MD, PhD Department of Vascular Disease University Medical Centre Ljubljana Slovenia DECLARATION OF CONFLICT OF INTEREST No conflict of interest
More informationPrimary Prevention of Stroke
Primary Prevention of Stroke Dr Chris Ellis Cardiologist Green Lane CVS Service, Auckland City Hospital & Auckland Heart Group, Mercy Hospital, Auckland 67 Pages Long, 735 References 29 Sub-Headings for
More informationUpdate on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient
Update on Dyslipidemia and Recent Data on Treating the Statin Intolerant Patient Steven E. Nissen MD Chairman, Department of Cardiovascular Medicine Cleveland Clinic Disclosure Consulting: Many pharmaceutical
More informationStable CAD, Elective Stenting and AFib
Stable CAD, Elective Stenting and AFib Kurt Huber, MD, FESC, FACC, FAHA 3 rd Medical Department Cardiology & Intensive Care Medicine Wilhelminenhospital & Sigmund Freud Private University, Medical School
More informationLDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
More informationClinical and Economic Value of Rivaroxaban in Coronary Artery Disease
CHRISTOPHER B. GRANGER, MD Professor of Medicine Division of Cardiology, Department of Medicine; Director, Cardiac Care Unit Duke University Medical Center, Durham, NC Clinical and Economic Value of Rivaroxaban
More informationIs there a mechanism of interaction between hypertension and dyslipidaemia?
Is there a mechanism of interaction between hypertension and dyslipidaemia? Neil R Poulter International Centre for Circulatory Health NHLI, Imperial College London Daegu, Korea April 2005 Observational
More informationA: Epidemiology update. Evidence that LDL-C and CRP identify different high-risk groups
A: Epidemiology update Evidence that LDL-C and CRP identify different high-risk groups Women (n = 27,939; mean age 54.7 years) who were free of symptomatic cardiovascular (CV) disease at baseline were
More informationGuidelines on cardiovascular risk assessment and management
European Heart Journal Supplements (2005) 7 (Supplement L), L5 L10 doi:10.1093/eurheartj/sui079 Guidelines on cardiovascular risk assessment and management David A. Wood 1,2 * 1 Cardiovascular Medicine
More informationWOEST ESC, Hotline III, Munchen, August 28th, 2012
ESC, Hotline III, Munchen, August 28th, 2012 The WOEST Trial: First randomised trial comparing two regimens with and without aspirin in patients on oral anticoagulant therapy undergoing coronary stenting
More informationShould I use statins?
I know the trials in heart failure but how do I manage my patient? Should I use statins? Aldo P Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Disclosures Aldo P Maggioni served as a member of
More informationSession Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia
GROUPE HOSPITALIER BICHAT-CLAUDE BERNARD PARIS DIDEROT UNIVERSITY - PARIS 7 Session Antiplatelet Therapy: How, Why and When? In patients with ischemic stroke/tia Pierre Amarenco INSERM U-698 and Denis
More informationThe TNT Trial Is It Time to Shift Our Goals in Clinical
The TNT Trial Is It Time to Shift Our Goals in Clinical Angioplasty Summit Luncheon Symposium Korea Assoc Prof David Colquhoun 29 April 2005 University of Queensland, Wesley Hospital, Brisbane, Australia
More informationPaolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia
Anticoagulanti e mono-antiaggregazione: a chi, quali e per quanto tempo Paolo Gresele Dipartimento di Medicina Sezione di Medicina Interna e Cardiovascolare Università di Perugia Anticoagulazione: Bologna,
More informationNSAIDs: The Truth About Cardiovascular Risk
NSAIDs: The Truth About Cardiovascular Risk Adam Grunbaum DO FACOI FACR American College of Osteopathic Internists Annual Convention and Scientific Sessions October 3 rd 2015 Disclosures none 2 Objectives
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More information